Cardiol Therapeutics (TSE:CRDL) Shares Up 11.4% – Here’s Why

Cardiol Therapeutics Inc. (TSE:CRDL)’s share price was up 11.4% on Thursday . The company traded as high as C$1.81 and last traded at C$1.76. Approximately 138,484 shares traded hands during trading, an increase of 46% from the average daily volume of 95,163 shares. The stock had previously closed at C$1.58.

Cardiol Therapeutics Stock Performance

The company has a quick ratio of 6.84, a current ratio of 4.39 and a debt-to-equity ratio of 0.48. The stock has a fifty day moving average price of C$1.62 and a 200-day moving average price of C$1.57. The firm has a market cap of C$202.88 million, a price-to-earnings ratio of -4.51 and a beta of 0.30.

Cardiol Therapeutics (TSE:CRDL) last posted its quarterly earnings data on Monday, May 11th. The company reported C($0.10) earnings per share for the quarter. On average, analysts expect that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.